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INTRODUCTION
Growing costs in health care are an important issue to be consi­
dered in public health. Among health technology assessment diffe­
rent types of studies, cost­effectiveness and cost­utility analysis are 
useful tools to compare both costs and results (measured as effecti­
veness or as quality of life, respectively) for different interventions(1 ­3). 
New treatment modalities need to be evaluated; in order to help 
decision makers to better allocate health resources(1).
Economic impact of most prevalent eye diseases and their treat­
ment is felt heavily on health services due especially to glaucoma, 
one of the leading causes of irreversible blindness in the world(4). The­
re is a trend of increasing costs in the future, as both incidence and 
prevalence of glaucoma are expected to be higher in the next years(5).
Glaucoma direct costs have a major impact on health care, be­
cause it includes: chronic use of medications, surgical procedures, 
medical visits and frequent exams(6). Glaucoma chargers are respon­
sible for up to 12% of all medical expenses in glaucoma patients(7). 
Medica tions contribute with a significant proportion of glaucoma 
re lated direct costs(6). Rylander and Vold estimated the annual costs 
with a single medication in the United States. It varied from US$ 150.81 
to US$ 873.98(8). If a patient needs more than one medication, which 
is not unusual(9,10), these costs are even higher.
The usual care in glaucoma is to initiate treatment with one medi­
cation (monotherapy)(11). If the target intraocular pressure (IOP) is not 
reached, a second and, not rarely, a third medication are added(9­11). 
Once the patient is already in a three­drug regimen (maximum me­
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RESUMO
Objetivo: A esclerectomia profunda não penetrante (EPNP) é uma opção viável para o 
tratamento cirúrgico do glaucoma de ângulo aberto. O objetivo deste estudo é avaliar a 
relação custo-efetividade da EPNP e compará-la com terapia clínica máxima (TCM) em 
um acompanhamento de 5 anos. 
Métodos: Um modelo de análise de decisão foi proposto comparando-se o tratamento 
cirúrgico (EPNP) versus a TCM. A avaliação da EPNP foi observacional retrospectiva de 
uma série consecutiva de casos e da TCM foi hipotética. A TCM foi considerada como o 
uso de três drogas (associação de uma combinação fixa de timolol/dorzolamida [CFTD] 
e um análogo de prostaglandina [bimatoprosta, latanoprosta ou travoprosta]). A relação 
cus to-efetividade foi definida com o custo direto (em dólares) para cada porcentual de 
redução da pressão intraocular (PIO). A razão de custo-efetividade incremental (ICER) 
foi calculada. O seguimento foi de 5 anos e a perspectiva dos custos é do Sistema Único 
de Saúde (SUS). 
Resultados: O custo direto para cada porcentual de redução da PIO ao final de 5 anos 
(relação custo-efetividade) foi de US$ 10,19 para a EPNP; US$ 37,45 para a CFTD + bima-
toprosta; US$ 39,33 para CFTD + travoprosta; e US$ 41,42 para CFTD + latanoprosta. A 
EPNP apresentou uma melhor relação custo-efetividade, quando comparada com a TCM. 
O índice ICER foi negativo, portanto a EPNP foi a opção terapêutica dominante. 
Conclusão: A EPNP foi menos custosa e mais efetiva que a TCM. Do ponto de vista do SUS, 
ela foi a opção mais custo-efetiva, quando comparada com a TCM.
Descritores: Glaucoma/economia; Cirurgia filtrante/economia; Custos de cuidados de 
saúde; Análise de custo-efetividade
ABSTRACT
Purpose: Non­penetrating deep sclerectomy (NPDS) has emerged as a viable option 
in the surgical management of open­angle glaucoma. Our aim is to assess the cost­
eff ectiveness of NPDS and to compare it to maximum medical treatment in a 5­year 
follow­up. 
Methods: A decision analysis model was built. Surgical (NPDS) arm of the decision 
tree was observational (consecutive retrospective case series) and maximum medical 
treatment arm was hypothetical. Maximum medical therapy was considered a three­
­drug regimen (association of a fixed combination of timolol/dorzolamide [FCTD] and 
a prostaglandin analogue [bimatoprost, latanoprost or travoprost]). Cost­effectiveness 
ratio was defined as direct cost (US dollars) for each percentage of intraocular pressure 
(IOP) reduction. Horizon was 5 years and perspective is from the public health care 
service in Brazil (SUS). Incremental cost­effectiveness ratio (ICER) was calculated. 
Results: Direct cost for each percentage of IOP reduction in 5 years (cost­effectiveness 
ratio) was US$ 10.19 for NPDS; US$ 37.45 for the association of a FCTD and bimatoprost; 
US$ 39.33 for FCTD and travoprost; and US$ 41.42 for FCTD and latanoprost. NPDS 
demonstrated a better cost­effectiveness ratio, compared to maximum medical therapy. 
The ICER was negative for all medical treatment options; therefore NPDS was dominant. 
Conclusions: Despite some limitations, NPDS was both less costly and more effective 
than maximum medical therapy. From the Brazilian public health perspective, it was 
the most cost­effective treatment option when compared to maximum medical the ­
rapy (FCTD and prostaglandin).
Keywords: Glaucoma/economy; Filtering surgery/economy; Health care costs; Cost­
eff ec tiveness evaluation
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dical therapy) and glaucoma is still progressing, it is usually the time 
for surgery(11). However, many patients and, even their doctors, some­
times refuse to accept or indicate the surgical procedure due to some 
surgery­related potential risks. Therefore, many patients are kept 
under maximum medical therapy for a long period of time, leading 
to problems related to chronic use of medications, such as: ocular 
surface toxicity, costs, adherence, persistence and quality of life(12).
Non­penetrating deep sclerectomy (NPDS) is a filtering glauco­
ma procedure, which is an alternative to trabeculectomy in patients 
with open­angle glaucoma(13,14). Many studies proved its efficacy and 
safety and it has been recently introduced in the glaucoma surgical 
management in Brazil(14­17). 
The aim of this study is to assess the cost­effectiveness of NPDS in 
a group of patients and to compare it to maximum medical therapy 
in a 5­year follow­up.
METHODS
A decision model was built in order to allow the comparison bet ­
ween the surgery group and the medication group (Figure 1). 
The surgical arm of the decision analysis tree was observational 
and its data was derived from a retrospective chart review of conse­
cutive cases submitted to NPDS in the same setting (Juiz de Fora ­ MG, 
Brazil), by the same surgical team, from 1999 to 2007. NPDS technique 
was described elsewhere(14). Inclusion criteria were: diagnosis of pri­
mary open­angle glaucoma under maximum medical therapy and at 
least 5 years of follow­up after surgery. If both eyes of a patient were 
eligible, the authors chose the first operated eye for study. Exclusion 
criteria were: other types of glaucoma and cataract surgery in the 
5­years of follow­up.
NPDS direct costs were based on the following variables: 
 • Price of NPDS paid by the Brazilian Public National Health System 
(SUS) using the code 04.05.05.032­1 (Glaucoma Filtering Sur­
gery). Prices were obtained through the internet in the SIGTAP 
table(18);
 • Price and number of MMC units used intraoperatively;
 • Price and number of medications used in the postoperative 
period. The authors estimated 1 bottle of 0.3% ciprofloxacin 
and 2 bottles of 0.1% dexamethasone per surgical intervention. 
Another bottle of steroid was also included for goniopuncture 
or when 5­FU injections were needed;
 • Price and number of 5­FU injections;
 • Price and number of Nd:YAG laser goniopunctures;
 • Price and number of surgical reinterventions;
 • Price, number and type of glaucoma medications needed after 
surgery and for how long this medication was necessary for up 
to 5 years of follow­up.
Costs of transportation, medical visits, exams, as well as indirect 
costs (loss of productivity) were not included in the analysis.
Total NPDS direct cost (in 5 years) was divided by the total num­
ber of eyes to find the direct cost per eye. In order to allow the com­
parison with medications, which are used in both eyes of the same 
patient, we divided the total cost of medications by two. So we could 
compare the costs per treated eye and not per patient.
Effectiveness was defined as the mean percentage of intraocular 
pressure (IOP) reduction from the preoperative period to the end of 
follow­up and was calculated as follows: [(mean baseline IOP ­ mean 
final IOP)/mean baseline IOP] x 100.
In order to evaluate the NPDS ability to control IOP and allow 
comparisons to literature, we also calculated different NPDS success 
rates: IOP <21 mmHg without medication; IOP <18 mmHg without 
medication and IOP <18 mmHg with or without medication. Any 
intra and postoperative difficulties or complications were registered.
Although the patients included in this study were under maxi­
mum medical therapy (fixed combination of timolol/dorzolamide 
and a prostaglandin), their 5­year cost estimation was hypothetical. 
We assumed the hypothesis that those patients were kept under me­
dication for the whole follow­up period (5 years) and projected the 
costs and effectiveness. The medications used as maximum medical 
therapy in this study were: fixed combination of timolol/dorzolamide 
(FCTD) associated with a prostaglandin analogue (bimatoprost or 
latanoprost or travoprost).
We used the average wholesale price (AWP) for the medications 
costs and their effectiveness was based on the literature. For the 
pros taglandin analogues effectiveness (mean percentage of IOP 
re duction), we chose to use Aptel et al. study(19). They performed a 
meta­analysis of randomized controlled trials involving prostaglan­
din analogues. We decided to use peak values (higher percentage 
Figure 1. Decision analysis tree comparing surgery (observational arm) versus maximum medical therapy group (hypothetical arm).
POAG= primary open-angle glaucoma; FCTD= fixed combination of 0.5% timolol maleate/2% dorzolamide; NPDS= non penetrating deep sclerectomy
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of IOP reduction) for effectiveness. For the additive effect of FCTD 
over the prostaglandin analogue, only two studies were found in the 
literature and all of them evaluated the IOP reduction effect of FCTD 
added to latanoprost(20,21). We assumed the same effect for the other 
two prostaglandin analogues (bimatoprost and travoprost). Between 
those two studies, we chose to use Hatanaka et al. study(21), because 
of the more appropriate methodology and because it was made in 
a Brazilian population.
All prices were obtained in January 2010 in “reais” (Brazil’s cur­
rency). The authors converted the “reais” values into US dollar values 
using January 22nd 2010 as reference (1 dollar = 1.82 “reais”).
Cost­effectiveness of each decision tree arm was calculated 
through the division of direct cost/eye by the mean percentage of 
IOP reduction and was defined as the cost for each percentage of IOP 
reduction over 5 years.
We calculated the incremental cost, incremental effectiveness 
and the incremental cost­effectiveness ratio (ICER).
We used a 3% discount rate.
Univariate sensitivity analysis was performed using IOP reduction 
trough (lower percentage of IOP reduction) values as prostaglandin 
analogues effectiveness and different discount rates (0%; 5% and 10%).
All statistical analysis were performed using SPSS 13 (SPSS Inc., 
Chicago, Illinois) and Microsoft Excel (Microsoft Inc., 2007). 
The Ethics Committee of the Federal University of Juiz de Fora 
approved this study.
RESULTS
Two­hundred twenty­eight eyes met the inclusion criteria, but 
57 were excluded due to missing data in their charts. One hundred 
seventy­one eyes were evaluated in the observational arm of the 
decision analysis tree. Table 1 shows the demographics of the studied 
population. NPDS direct costs and resources used are demonstrated 
in table 2.
In the NPDS arm, mean preoperative IOP was 24.28 mmHg and 
mean final IOP was 12.95 mmHg (p<0.001; Paired Student T Test). 
Mean percentage of IOP reduction was 46.66% from baseline to 
the end of follow­up. Success rates were: 70.76% (IOP <21 mmHg 
without medication); 68.42% (IOP <18 mmHg without medication); 
and 90.64% (IOP <18 mmHg with or without medication). Intraope­
rative complications were few: conversion to trabeculectomy (4.7%) 
and microperforations (14%). Postoperative complication rates were 
also low: hyphema (0.06%); choroidal detachment (0.06%); shallow 
anterior chamber (1.8%); bleb leaks (3.5%); bleb fibrosis (19.3%).
In the maximum medical therapy arm, costs are displayed in 
table 3 and mean percentage of IOP reduction varied from 26.98% 
(8PM) to 33.08% (8AM) for bimatoprost; from 24.49% (8PM) to 33.46% 
(8AM) for latanoprost and from 26.52% (4PM) to 30.98% (8AM) for tra­
voprost. Peak values used for cost­effectiveness analysis were those 
from 8AM and trough values used for sensitivity analysis were those 
from 8PM for bimatoprost and latanoprost and 4PM for travoprost. 
Additive effect of FCTD found in the literature was 8.7%.
Cost­effectiveness results, incremental cost and incremental ef­
fec tiveness are displayed in table 4. NPDS was both less costly and 
more effective than maximum medical therapy; therefore it was 
dominant.
Sensitivity analysis using trough values for IOP reduction effect 
did not show any differences and NPDS still remained dominant over 
the other treatment options. Results were not interfered by different 
discount rates (0%; 5% and 10%). 
DISCUSSION
Our results show that NPDS demonstrated a better cost­effec­
tiveness ratio, compared to maximum medical therapy and it was 
dominant over all the studied treatment options. NPDS presented 
the lowest direct cost for each percentage of IOP reduction in 5 years 
(cost­effectiveness ratio).
Taking into consideration the assumptions of our study and 
from the Brazilian public health care provider perspective, surgery 
(NPDS) is the most cost­effective treatment option in patients under 
maximum medical therapy for glaucoma over a 5­year period. These 
results should not be different for another surgical option, trabecu­
lectomy, as literature has shown similar long­term results for both 
techniques(13­17). The main differences between these two techniques 
are early postoperative comfort and number of complications. Tra­
beculectomy patients face more complications in that period than 
NPDS patients(13­17). Costs for both techniques should not be very 
different, but it is a matter for further investigation.
We chose to use the mean percentage of IOP reduction as our 
effectiveness outcome measure, in order to make comparisons with 
medications easier. NPDS had the highest percentage of IOP re­
duction over 5 years (46.66%) and medications varied from 39.68% 
(FCTD and travoprost) to 42.16% (FCTD and latanoprost). Differences 
among medical therapies effectiveness values are not clinically sig­
nificant. NPDS effectiveness is in agreement with the literature for 
any glaucoma filtering procedure (both NPDS and trabeculectomy). 
Results in the literature show an IOP reduction between 44% and 
47% for NPDS(13­17). Lichter et al. found values between 45% and 48% 
in the CIGTS (Collaborative Initial Glaucoma Treatment Study) for the 
trabeculectomy group(10).
Despite very similar effectiveness results for the three medical 
the rapies (39.68%; 41.78% and 42.16%), in our cost­effectiveness 
analysis, some differences appear among them, mainly because their 
costs are not the same. Our results show that the most effective me­
dical treatment (FCTD + latanoprost) is not the most cost­effective. 
Table 1. Demographics of the population submitted to non-penetra-
ting deep sclerectomy surgery (observational group)
Population characteristics (n=171)





Pre­IOP (mmHg) mean ± standard deviation 24.28 ± 5.21
C/D 0.75 ± 0.14
Visual field stage  




IOP= intraocular pressure; C/D= cup to disc vertical ratio
Table 2. NPDS cost composition in a 5-year follow-up
NPDS cost composition Unit Cost (US$) Units Total Cost (US$)
NPDS 282.06 171 48,232.26
Resources used Mitomycin C 032.42 159 05,154.78
5­Fluoro­uracyl 015.39 051 00784.89
Goniopuncture 024.73 037 00915.01
New surgery 282.06 042 11,846.52
Medications* NA NA 27,292.60
Total cost A NA NA 94,226.06
Total cost per eye (= Total cost A ÷ 171) NA NA 00551.03
NPDS= non­penetrating deep sclerectomy
*= medications costs included all necessary antibiotics, steroids and any hypotensive 
medication needed in the postoperative period up to 5 years of follow­up
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effectiveness (%) ICER (US$/%)
NPDS 0475.32 46.66 10.19
FCTD + travoprost 1,560.70 39.68 39.33 1,085.38 ­6.98 Dominated
FCTD + bimatoprost 1,564.58 41.78 37.45 1,089.26 ­4.88 Dominated
FCTD + latanoprost 1,746.18 42.16 41.42 1,270.86 ­4.50 Dominated
NPDS= non­penetrating deep sclerectomy; FCTD= fixed combination of 0.5% timolol and 2% dorzolamide; ICER= incremental cost­effectiveness ratio
*= discount rate applied
Table 3. Medical therapy groups costs
Treatment AWP (US$) Daily cost per eye (US$) Monthly cost per eye (US$) Yearly cost per eye (US$) 5-Year cost per eye (US$)
FCTD + bimatoprost 096.96 1.01 30.23 362.76 1,813.78
FCTD + latanoprost 108.43 1.13 33.74 404.86 2,024.30
FCTD + travoprost 093.20 1.00 30.16 361.86 1,809.28
FCTD= fixed combination of 0.5% timolol and 2% dorzolamide; AWP=  average wholesale price
Actually, our data demonstrated that it had the worst cost­effective­
ness ratio. It can be explained by the highest cost of this treatment 
option compared to the others. Recently, we have observed a trend 
in lowering the costs of all prostaglandins analogues, as generic for­
mulations become available. This can cause an impact on our results 
and needs to have further investigation. 
Efficacy of NPDS is already proven in the literature. Two meta­
ana lysis investigations found similar success rates. To achieve an IOP 
<21 mmHg without medication, Cheng et al. found 67.8% (95% con­
fidence interval [CI]: 61.4%­74.3%) of success(15). Hondur et al. found 
a success rate of 67.1% for NPDS with antimetabolite(16). Our study 
showed a success rate (IOP < 21 mmHg without medication) slightly 
above those found in the literature (70.76%), but within the limits for 
the 95% CI found by Cheng et al.(15).
The majority of our cases (84.8%) had moderate to advanced 
visual field loss. According to the Advanced Glaucoma Intervention 
Study (AGIS)(23), these kinds of patients need target pressures below 
18 mmHg in all measures, with a mean IOP close to 12.3 mmHg to 
avoid progression. At the end of follow­up (5 years), IOP <18 mmHg 
without any medication, and with­or­without medication was achie­
ved in 68.42% and 90.64% of studied eyes, respectively. The mean IOP 
after 5 years of surgery was 12.95 mmHg, reaffirming NPDS’ ability to 
achieve target IOP in the great majority of eyes.
Intra and postoperative complications rates were similar to other 
published studies(13­17). The most frequent complication was filtering 
bleb fibrosis (19.3%). This explains the number of 5­FU injections (51 
injections) and reoperations (42/171). All eyes submitted to a second 
NPDS were well controlled up to 5 years of follow­up.
The authors did not take into consideration persistence and adhe ­
rence to medical therapy, as medications evaluations were hypothe­
tical. These can influence our results, as the duration of the bottle can 
vary according to those parameters.
Another limitation is that medication prices were based on the 
average wholesale price. Health care providers usually buy a large 
quantity of bottles, thereby receiving discounts and minimizing 
costs. Accordingly, an individual can benefit from pharmacy dis­
counts.
NPDS direct cost calculation excluded medical visits and exams. 
This can limit our findings, as an operated patient tends to need more 
visits than a patient under medical therapy. From the health care 
provider (payer) perspective, this influence is minimized as most of 
postoperative visits occur within the first month, when costs are still 
included in the surgical procedure charges. An increase in indirect 
costs (absence from work) is expected to happen and needs to be 
investigated. The eyes submitted to NPDS were in different glauco­
ma stages, which can influence the amount of resources used (5­FU 
needling, medications, etc) and, therefore, their costs in the posto­
perative period. We speculate that more advanced glaucomas tend 
to need more resources and generate more costs than early ones. 
However, we chose to use all glaucoma stages in order to simulate 
the “real world” where indication of surgery can occur in both early 
and advanced glaucomas.
We also excluded from our analysis the need for cataract surgery 
in both arms (surgical and medical therapy). Cataract formation or 
progression is an important issue to consider after trabeculectomy, 
but not after NPDS. The majority of authors believe that NPDS does 
not interfere with cataract formation or progression(13). We chose 
not to include cataract surgery on our analysis to keep our model as 
simple as possible and to avoid any influence of the cataract surgery 
on patient’s IOP.
The most cost­effective medication is not always the best the­
rapy. The most cost­effective prostaglandin analogue in every study 
was bimatoprost, which is known however to have poor persisten­
ce(24­27). Surgical complications can also have a negative impact on 
patient’s perceived quality of life. Incorporating quality of life as an 
effectiveness outcome measure would be useful and a cost­utility 
analysis on that matter would be interesting. Therefore, it is important 
to consider our results in a societal and collective perspective and 
applicable only for patients covered by the Brazilian public health 
service (SUS). Supplementary or private health services practice other 
prices and in these realities, our results could be entirely different. 
Adaptations must be done on an individual basis.
In our study, taking into consideration all assumptions and limi­
tations, NPDS was both less costly and more effective than maximum 
medical therapy. From the Brazilian public health service (SUS) pers­
pective, NPDS was the most cost­effective treatment option when 
compared to maximum medical therapy (FCTD and prostaglandin) 
over a 5­year period.
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